{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0.59","upperLimit":"9.6","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"description":"Time from enrollment to disease progression, diagnosis of a second malignant neoplasm, death or last follow-up, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients in phase I received vorinostat at 180 mg/m\\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\\^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\n3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo intensity-modulated radiation therapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Arm 1, Phase I Vorinostat 180 mg/m^2"},{"description":"Patients received a higher dose of vorinostat at 230 mg/m\\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\\^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\n3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo intensity-modulated radiation therapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG001","title":"Arm 2, Phase I Vorinostat 230 mg/m^2"},{"description":"Patients received a higher dose of vorinostat at 230 mg/m\\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\\^2/ day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\n3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo intensity-modulated radiation therapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG002","title":"Arm 3, Phase II Evaluation Vorinostat 230 mg/m^2"}],"paramType":"NUMBER","populationDescription":"One patient enrolled on Arm 3 was withdrawn from study prior to the start of treatment.","reportingStatus":"POSTED","timeFrame":"2 years after study enrollment","title":"Event-Free Survival","type":"PRIMARY","unitOfMeasure":"percent probability"}